Stem Cell Therapy for Epidermolysis Bullosa in a Young Patient

Understanding Epidermolysis Bullosa

A recent study published in Nature highlights a groundbreaking therapy utilizing stem cells to treat a 7-year-old boy diagnosed with epidermolysis bullosa (EB). This genetically inherited condition is characterized by severe skin fragility and blistering, where even minor skin irritations can lead to significant skin loss and potentially life-threatening infections. The daily management of EB, which includes painful skin care procedures, can exceed costs of $100,000 USD annually.

Children with EB often experience chronic anticipatory anxiety, depression, and behavioral issues, significantly impacting their quality of life due to ongoing discomfort and the demands of their care routines.

Case Study Overview

In a related case study featured in Science Magazine, researchers explored a novel stem cell therapy approach for treating EB in the same 7-year-old boy. EB is typically induced by genetic mutations affecting one or multiple genes that connect the epidermis (outer skin layer) to the dermis (inner skin layer). The boy, from Germany, was diagnosed with a severe form of junctional EB, lacking a critical protein required for the adhesion of these skin layers.

To initiate treatment, researchers harvested a small patch of skin from the boy’s groin, approximately the size of a Canadian loonie. They then genetically modified the skin stem cells to produce the essential protein. Following multiple clinical safety assessments, the corrected stem cells were grafted onto the boy’s arms, legs, back, and chest in two surgical procedures.

Results and Implications

After a month of recovery, researchers observed the formation of new, healthy skin in the grafted areas, with no blistering present. Although many of the grafted cells perished shortly after the procedure, the surviving stem cells proliferated throughout the boy’s body, resulting in nearly entirely healthy skin by the eight-month mark.

These promising early results indicate that stem cell therapy could be a viable treatment option for individuals with EB. However, researchers caution that this approach is not universally applicable, as most cases of EB arise from a single gene mutation, while others involve multiple mutations, complicating potential treatment strategies.

Future Directions

Scientists are optimistic about employing CRISPR genome editing technology to address the challenges posed by multiple gene mutations, as it has shown potential in correcting several genetic anomalies simultaneously. While this trial represents significant progress in alleviating the skin-related symptoms of EB, it does not address the internal damage caused by the disease, thus preventing it from being considered a complete “cure.”

Currently, biotechnology firms are collaborating with the researchers from this study to further investigate the effectiveness of stem cell therapy in treating a larger cohort of EB patients.

References

1. Servick, Kelly. “A boy with a rare disease gets new skin, thanks to gene-corrected stem cells.” 8 November 2017. http://www.sciencemag.org/news/2017/11/boy-rare-disease-gets-new-skin-thanks-gene-corrected-stem-cells
2. Puvabanditsin S, Mehta R, McConnel JA, Gengel NK, Mayne J, Walzer L. “Pediatric Epidermolysis Bullosa Treatment & Management.” 7 February 2017. https://emedicine.medscape.com/article/909549-treatment
3. “Epidermolysis Bullosa.” SickKids. http://www.sickkids.ca/Dermatology/What-we-do/Epidermolysis-bullosa/index.html